"FDA Probes Ozempic and Similar Drugs for Potential Hair Loss, Suicidal Thoughts Amid Weight-Loss Benefits"

The FDA is reviewing side effects reported with GLP-1 receptor agonists like Ozempic, Mounjaro, and Wegovy, used for diabetes and weight loss. Side effects under investigation include hair loss, suicidal thoughts, and aspiration. While the FDA has not established a causal relationship between the drugs and these risks, they are assessing the need for regulatory actions such as label changes. Patients are advised to consult healthcare providers about concerns, and the FDA continues to monitor drug safety post-approval. Novo Nordisk and Eli Lilly, manufacturers of these drugs, emphasize patient safety and are cooperating with the FDA.